MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network

•Updated clinical guidance on MDR-TB is needed.•Several new MDR-TB diagnostics have been recently approved by WHO to complement existing tools.•To design a regimen, 4–5 active drugs are needed with a treatment duration up to 24 months.•Post-treatment sequelae might require pulmonary rehabilitation.•...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of infectious diseases Jg. 92; S. S15 - S25
Hauptverfasser: Migliori, Giovanni Battista, Tiberi, Simon, Zumla, Alimuddin, Petersen, Eskild, Chakaya, Jeremiah Muhwa, Wejse, Christian, Muñoz Torrico, Marcela, Duarte, Raquel, Alffenaar, Jan Willem, Schaaf, H. Simon, Marais, Ben J., Cirillo, Daniela Maria, Alagna, Riccardo, Rendon, Adrian, Pontali, Emanuele, Piubello, Alberto, Figueroa, José, Ferlazzo, Gabriella, García-Basteiro, Alberto, Centis, Rosella, Visca, Dina, D’Ambrosio, Lia, Sotgiu, Giovanni, Arkub, T. Abu, Akkerman, O.W., Aleksa, A., Belilovski, E., Bernal, E., Blanc, F-X., Boeree, M., Borisov, S., Bruchfeld, J., Cadiñanos Loidi, J., Caminero, J.A., Carvalho, A.C., Cebrian Gallardo, J.J., Charalampos, Danila, E., Davies Forsman, L., Denholm, J., Dheda, K., Diel, R., Diktanas, S., Dobler, C., Enwerem, M., Esposito, S., Escobar Salinas, N., Filippov, A., Formenti, B., García García, J.M., Goletti, D., Gomez Rosso, R., Gualano, G., Isaakidis, P., Kaluzhenina, A., Koirala, S., Kuksa, L., Kunst, H., Li, Y., Magis-Escurra, C., Manfrin, V., Manga, S., Manika, K., Marchese, V., Martínez Robles, E., Maryandyshev, A., Matteelli, A., Mariani, A., Mazza-Stalder, J., Mello, F., Mendoza, L., Mesi, A., Miliauskas, S., Mustafa Hamdan, H., Ndjeka, N., Nieto Marcos, M., Ottenhoff, T.H.M., Palmero, D.J., Palmieri, F., Papavasileiou, A., Payen, M.C., Pontarelli, A., Pretti Dalcolmo, M., Quirós Fernandez, S., Romero, R., Rossato Silva, D., Santos, A.P., Seaworth, B., Sinitsyn, M., Skrahina, A., Solovic, I., Spanevello, A., Tadolini, M., Torres, C., Udwadia, Z., van den Boom, M., Volchenkov, G.V., Yedilbayev, A., Zaleskis, R., Zellweger, J.P.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Canada Elsevier Ltd 01.03.2020
Elsevier
Schlagworte:
Diagnosis
MDR-TB
Prevention
Rehabilitation of sequelae
Treatment
XDR-TB
Prevention
MDR-TB
Treatment
XDR-TB
Diagnosis
Rehabilitation of sequelae
ISSN:1201-9712, 1878-3511, 1878-3511
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract •Updated clinical guidance on MDR-TB is needed.•Several new MDR-TB diagnostics have been recently approved by WHO to complement existing tools.•To design a regimen, 4–5 active drugs are needed with a treatment duration up to 24 months.•Post-treatment sequelae might require pulmonary rehabilitation.•LTBI management and infection control are core elements of the MDR-TB public health approach. The continuous flow of new research articles on MDR-TB diagnosis, treatment, prevention and rehabilitation requires frequent update of existing guidelines. This review is aimed at providing clinicians and public health staff with an updated and easy-to-consult document arising from consensus of Global Tuberculosis Network (GTN) experts. The core published documents and guidelines have been reviewed, including the recently published MDR-TB WHO rapid advice and ATS/CDC/ERS/IDSA guidelines. After a rapid review of epidemiology and risk factors, the clinical priorities on MDR-TB diagnosis (including whole genome sequencing and drug-susceptibility testing interpretations) and treatment (treatment design and management, TB in children) are discussed. Furthermore, the review comprehensively describes the latest information on contact tracing and LTBI management in MDR-TB contacts, while providing guidance on post-treatment functional evaluation and rehabilitation of TB sequelae, infection control and other public health priorities.
AbstractList The continuous flow of new research articles on MDR-TB diagnosis, treatment, prevention and rehabilitation requires frequent update of existing guidelines. This review is aimed at providing clinicians and public health staff with an updated and easy-to-consult document arising from consensus of Global Tuberculosis Network (GTN) experts.The core published documents and guidelines have been reviewed, including the recently published MDR-TB WHO rapid advice and ATS/CDC/ERS/IDSA guidelines.After a rapid review of epidemiology and risk factors, the clinical priorities on MDR-TB diagnosis (including whole genome sequencing and drug-susceptibility testing interpretations) and treatment (treatment design and management, TB in children) are discussed. Furthermore, the review comprehensively describes the latest information on contact tracing and LTBI management in MDR-TB contacts, while providing guidance on post-treatment functional evaluation and rehabilitation of TB sequelae, infection control and other public health priorities. Keywords: MDR-TB, XDR-TB, Diagnosis, Treatment, Prevention, Rehabilitation of sequelae
The continuous flow of new research articles on MDR-TB diagnosis, treatment, prevention and rehabilitation requires frequent update of existing guidelines. This review is aimed at providing clinicians and public health staff with an updated and easy-to-consult document arising from consensus of Global Tuberculosis Network (GTN) experts. The core published documents and guidelines have been reviewed, including the recently published MDR-TB WHO rapid advice and ATS/CDC/ERS/IDSA guidelines. After a rapid review of epidemiology and risk factors, the clinical priorities on MDR-TB diagnosis (including whole genome sequencing and drug-susceptibility testing interpretations) and treatment (treatment design and management, TB in children) are discussed. Furthermore, the review comprehensively describes the latest information on contact tracing and LTBI management in MDR-TB contacts, while providing guidance on post-treatment functional evaluation and rehabilitation of TB sequelae, infection control and other public health priorities.The continuous flow of new research articles on MDR-TB diagnosis, treatment, prevention and rehabilitation requires frequent update of existing guidelines. This review is aimed at providing clinicians and public health staff with an updated and easy-to-consult document arising from consensus of Global Tuberculosis Network (GTN) experts. The core published documents and guidelines have been reviewed, including the recently published MDR-TB WHO rapid advice and ATS/CDC/ERS/IDSA guidelines. After a rapid review of epidemiology and risk factors, the clinical priorities on MDR-TB diagnosis (including whole genome sequencing and drug-susceptibility testing interpretations) and treatment (treatment design and management, TB in children) are discussed. Furthermore, the review comprehensively describes the latest information on contact tracing and LTBI management in MDR-TB contacts, while providing guidance on post-treatment functional evaluation and rehabilitation of TB sequelae, infection control and other public health priorities.
•Updated clinical guidance on MDR-TB is needed.•Several new MDR-TB diagnostics have been recently approved by WHO to complement existing tools.•To design a regimen, 4–5 active drugs are needed with a treatment duration up to 24 months.•Post-treatment sequelae might require pulmonary rehabilitation.•LTBI management and infection control are core elements of the MDR-TB public health approach. The continuous flow of new research articles on MDR-TB diagnosis, treatment, prevention and rehabilitation requires frequent update of existing guidelines. This review is aimed at providing clinicians and public health staff with an updated and easy-to-consult document arising from consensus of Global Tuberculosis Network (GTN) experts. The core published documents and guidelines have been reviewed, including the recently published MDR-TB WHO rapid advice and ATS/CDC/ERS/IDSA guidelines. After a rapid review of epidemiology and risk factors, the clinical priorities on MDR-TB diagnosis (including whole genome sequencing and drug-susceptibility testing interpretations) and treatment (treatment design and management, TB in children) are discussed. Furthermore, the review comprehensively describes the latest information on contact tracing and LTBI management in MDR-TB contacts, while providing guidance on post-treatment functional evaluation and rehabilitation of TB sequelae, infection control and other public health priorities.
The continuous flow of new research articles on MDR-TB diagnosis, treatment, prevention and rehabilitation requires frequent update of existing guidelines. This review is aimed at providing clinicians and public health staff with an updated and easy-to-consult document arising from consensus of Global Tuberculosis Network (GTN) experts. The core published documents and guidelines have been reviewed, including the recently published MDR-TB WHO rapid advice and ATS/CDC/ERS/IDSA guidelines. After a rapid review of epidemiology and risk factors, the clinical priorities on MDR-TB diagnosis (including whole genome sequencing and drug-susceptibility testing interpretations) and treatment (treatment design and management, TB in children) are discussed. Furthermore, the review comprehensively describes the latest information on contact tracing and LTBI management in MDR-TB contacts, while providing guidance on post-treatment functional evaluation and rehabilitation of TB sequelae, infection control and other public health priorities.
Author Rendon, Adrian
Diel, R.
Li, Y.
Manika, K.
Nieto Marcos, M.
Belilovski, E.
Mustafa Hamdan, H.
Martínez Robles, E.
Ndjeka, N.
Tiberi, Simon
Payen, M.C.
Boeree, M.
Torres, C.
Zaleskis, R.
Wejse, Christian
Filippov, A.
D’Ambrosio, Lia
Mazza-Stalder, J.
Gomez Rosso, R.
Manfrin, V.
Mesi, A.
Matteelli, A.
Alagna, Riccardo
Caminero, J.A.
Isaakidis, P.
van den Boom, M.
Pontali, Emanuele
Davies Forsman, L.
Manga, S.
Palmero, D.J.
Chakaya, Jeremiah Muhwa
Formenti, B.
Skrahina, A.
Gualano, G.
Migliori, Giovanni Battista
García-Basteiro, Alberto
Spanevello, A.
Mariani, A.
Akkerman, O.W.
Piubello, Alberto
Dobler, C.
Danila, E.
Kuksa, L.
Magis-Escurra, C.
Santos, A.P.
Marais, Ben J.
Sinitsyn, M.
Udwadia, Z.
Borisov, S.
Ferlazzo, Gabriella
Arkub, T. Abu
Carvalho, A.C.
Centis, Rosella
Pontarelli, A.
Aleksa, A.
Seaworth, B.
Denholm, J.
Tadolini, M.
Sotgiu, Giovanni
Duarte, Raquel
Figueroa, José
Visca, Dina
Rossato Silva, D.
Enwerem, M.
Muñoz Torrico, Marcela
Palmieri, F.
Ottenhoff, T.H.M.
Cirillo, Daniela Maria
Maryandyshev, A.
Kaluzhenina, A.
Cebrian Gallardo, J.J.
Bruchf
Author_xml – sequence: 1
  givenname: Giovanni Battista
  orcidid: 0000-0002-2597-574X
  surname: Migliori
  fullname: Migliori, Giovanni Battista
  email: giovannibattista.migliori@icsmaugeri.it
  organization: Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Via Roncaccio 16, Tradate, Varese, 21049, Italy
– sequence: 2
  givenname: Simon
  surname: Tiberi
  fullname: Tiberi, Simon
  email: simon.tiberi@nhs.net
  organization: Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
– sequence: 3
  givenname: Alimuddin
  orcidid: 0000-0002-5111-5735
  surname: Zumla
  fullname: Zumla, Alimuddin
  email: a.i.zumla@gmail.com
  organization: Division of Infection and Immunity, University College London and NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, United Kingdom
– sequence: 4
  givenname: Eskild
  orcidid: 0000-0002-8793-9680
  surname: Petersen
  fullname: Petersen, Eskild
  email: eskild.petersen@gmail.com
  organization: Directorate General for Disease Surveillance and Control, Ministry of Health, Muscat, Oman
– sequence: 5
  givenname: Jeremiah Muhwa
  orcidid: 0000-0002-3229-2429
  surname: Chakaya
  fullname: Chakaya, Jeremiah Muhwa
  email: chakaya.jm@gmail.com
  organization: The International Union Against Tuberculosis and Lung Disease, Paris, France
– sequence: 6
  givenname: Christian
  orcidid: 0000-0002-2534-2942
  surname: Wejse
  fullname: Wejse, Christian
  email: wejse@dadlnet.dk
  organization: Department of Infectious Disease, Aarhus University Hospital and School of Public Health, Faculty of Health Sciences, University of Aarhus, Denmark
– sequence: 7
  givenname: Marcela
  surname: Muñoz Torrico
  fullname: Muñoz Torrico, Marcela
  email: dra_munoz@hotmail.com
  organization: Clínica de Tuberculosis, Instituto Nacional de Enfermedades Respiratorias, Ciudad de México, Mexico
– sequence: 8
  givenname: Raquel
  orcidid: 0000-0003-2257-3099
  surname: Duarte
  fullname: Duarte, Raquel
  email: raquelafduarte@gmail.com
  organization: National Reference Centre for MDR-TB, Hospital Centre Vila Nova de Gaia, Department of Pneumology, Public Health Science and Medical Education Department, Faculty of Medicine, University of Porto, Porto, Portugal
– sequence: 9
  givenname: Jan Willem
  orcidid: 0000-0001-6703-0288
  surname: Alffenaar
  fullname: Alffenaar, Jan Willem
  email: j.w.c.alffenaar@umcg.nl
  organization: Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
– sequence: 10
  givenname: H. Simon
  surname: Schaaf
  fullname: Schaaf, H. Simon
  email: hss@sun.ac.za
  organization: Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa
– sequence: 11
  givenname: Ben J.
  orcidid: 0000-0003-3404-2690
  surname: Marais
  fullname: Marais, Ben J.
  email: ben.marais@health.nsw.gov.au
  organization: The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia
– sequence: 12
  givenname: Daniela Maria
  surname: Cirillo
  fullname: Cirillo, Daniela Maria
  email: cirillo.daniela@hsr.it
  organization: Emerging Pathogens Unit, TB Supranational Reference Laboratory, San Raffaele Scientific Institute, Milan, Italy
– sequence: 13
  givenname: Riccardo
  surname: Alagna
  fullname: Alagna, Riccardo
  email: alagna.riccardo@hsr.it
  organization: Emerging Pathogens Unit, TB Supranational Reference Laboratory, San Raffaele Scientific Institute, Milan, Italy
– sequence: 14
  givenname: Adrian
  surname: Rendon
  fullname: Rendon, Adrian
  email: adrianrendon@hotmail.com
  organization: Centro de Investigación, Prevención y Tratamiento de Infecciones Respiratorias CIPTIR, University Hospital of Monterrey UANL (Universidad Autonoma de Nuevo Leon), Monterrey, Mexico
– sequence: 15
  givenname: Emanuele
  surname: Pontali
  fullname: Pontali, Emanuele
  email: pontals@yahoo.com
  organization: Department of Infectious Diseases, Galliera Hospital, Genova, Italy
– sequence: 16
  givenname: Alberto
  surname: Piubello
  fullname: Piubello, Alberto
  email: albertopiubello@yahoo.it
  organization: The International Union Against Tuberculosis and Lung Disease, Paris, France
– sequence: 17
  givenname: José
  surname: Figueroa
  fullname: Figueroa, José
  email: josefigueroa@doctors.org.uk
  organization: National Health Service (NHS) England, London, United Kingdom
– sequence: 18
  givenname: Gabriella
  surname: Ferlazzo
  fullname: Ferlazzo, Gabriella
  email: Gabriella.FERLAZZO@joburg.msf.org
  organization: Southern Africa Medical Unit, Médecins Sans Frontières, Cape Town, South Africa
– sequence: 19
  givenname: Alberto
  surname: García-Basteiro
  fullname: García-Basteiro, Alberto
  email: alberto.garcia-basteiro@manhica.net
  organization: Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique
– sequence: 20
  givenname: Rosella
  surname: Centis
  fullname: Centis, Rosella
  email: rosella.centis@icsmaugeri.it
  organization: Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Via Roncaccio 16, Tradate, Varese, 21049, Italy
– sequence: 21
  givenname: Dina
  surname: Visca
  fullname: Visca, Dina
  email: dina.visca@icsmaugeri.it
  organization: Division of Pulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri, IRCCS, Tradate, Italy
– sequence: 22
  givenname: Lia
  surname: D’Ambrosio
  fullname: D’Ambrosio, Lia
  email: liadambrosio59@gmail.com
  organization: Public Health Consulting Group, Lugano, Switzerland
– sequence: 23
  givenname: Giovanni
  orcidid: 0000-0002-1600-4474
  surname: Sotgiu
  fullname: Sotgiu, Giovanni
  email: gsotgiu@uniss.it
  organization: Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy
– sequence: 24
  givenname: T. Abu
  surname: Arkub
  fullname: Arkub, T. Abu
  organization: Russian Federation
– sequence: 25
  givenname: O.W.
  surname: Akkerman
  fullname: Akkerman, O.W.
  organization: Netherlands
– sequence: 26
  givenname: A.
  surname: Aleksa
  fullname: Aleksa, A.
  organization: Belarus
– sequence: 27
  givenname: E.
  surname: Belilovski
  fullname: Belilovski, E.
  organization: Russian Federation
– sequence: 28
  givenname: E.
  surname: Bernal
  fullname: Bernal, E.
  organization: Spain
– sequence: 29
  givenname: F-X.
  surname: Blanc
  fullname: Blanc, F-X.
  organization: France
– sequence: 30
  givenname: M.
  surname: Boeree
  fullname: Boeree, M.
  organization: Netherlands
– sequence: 31
  givenname: S.
  surname: Borisov
  fullname: Borisov, S.
  organization: Russian Federation
– sequence: 32
  givenname: J.
  surname: Bruchfeld
  fullname: Bruchfeld, J.
  organization: Sweden
– sequence: 33
  givenname: J.
  surname: Cadiñanos Loidi
  fullname: Cadiñanos Loidi, J.
  organization: Spain
– sequence: 34
  givenname: J.A.
  surname: Caminero
  fullname: Caminero, J.A.
  organization: Spain
– sequence: 35
  givenname: A.C.
  surname: Carvalho
  fullname: Carvalho, A.C.
  organization: Brazil
– sequence: 36
  givenname: J.J.
  surname: Cebrian Gallardo
  fullname: Cebrian Gallardo, J.J.
  organization: Spain
– sequence: 37
  surname: Charalampos
  fullname: Charalampos
  organization: Greece
– sequence: 38
  givenname: E.
  surname: Danila
  fullname: Danila, E.
  organization: Lithuania
– sequence: 39
  givenname: L.
  surname: Davies Forsman
  fullname: Davies Forsman, L.
  organization: Sweden
– sequence: 40
  givenname: J.
  surname: Denholm
  fullname: Denholm, J.
– sequence: 41
  givenname: K.
  surname: Dheda
  fullname: Dheda, K.
  organization: South Africa
– sequence: 42
  givenname: R.
  surname: Diel
  fullname: Diel, R.
  organization: Germany
– sequence: 43
  givenname: S.
  surname: Diktanas
  fullname: Diktanas, S.
  organization: Lithuania
– sequence: 44
  givenname: C.
  surname: Dobler
  fullname: Dobler, C.
  organization: Australia
– sequence: 45
  givenname: M.
  surname: Enwerem
  fullname: Enwerem, M.
  organization: South Africa
– sequence: 46
  givenname: S.
  surname: Esposito
  fullname: Esposito, S.
  organization: Italy
– sequence: 47
  givenname: N.
  surname: Escobar Salinas
  fullname: Escobar Salinas, N.
  organization: Chile
– sequence: 48
  givenname: A.
  surname: Filippov
  fullname: Filippov, A.
  organization: Russian Federation
– sequence: 49
  givenname: B.
  surname: Formenti
  fullname: Formenti, B.
  organization: Italy
– sequence: 50
  givenname: J.M.
  surname: García García
  fullname: García García, J.M.
  organization: Spain
– sequence: 51
  givenname: D.
  surname: Goletti
  fullname: Goletti, D.
  organization: Italy
– sequence: 52
  givenname: R.
  surname: Gomez Rosso
  fullname: Gomez Rosso, R.
  organization: Paraguay
– sequence: 53
  givenname: G.
  surname: Gualano
  fullname: Gualano, G.
  organization: Italy
– sequence: 54
  givenname: P.
  surname: Isaakidis
  fullname: Isaakidis, P.
  organization: South Africa
– sequence: 55
  givenname: A.
  surname: Kaluzhenina
  fullname: Kaluzhenina, A.
  organization: Russian Federation
– sequence: 56
  givenname: S.
  surname: Koirala
  fullname: Koirala, S.
  organization: Nepal
– sequence: 57
  givenname: L.
  surname: Kuksa
  fullname: Kuksa, L.
  organization: Latvia
– sequence: 58
  givenname: H.
  surname: Kunst
  fullname: Kunst, H.
  organization: UK
– sequence: 59
  givenname: Y.
  surname: Li
  fullname: Li, Y.
  organization: China
– sequence: 60
  givenname: C.
  surname: Magis-Escurra
  fullname: Magis-Escurra, C.
  organization: Netherlands
– sequence: 61
  givenname: V.
  surname: Manfrin
  fullname: Manfrin, V.
  organization: Italy
– sequence: 62
  givenname: S.
  surname: Manga
  fullname: Manga, S.
  organization: Peru
– sequence: 63
  givenname: K.
  surname: Manika
  fullname: Manika, K.
  organization: Greece
– sequence: 64
  givenname: V.
  surname: Marchese
  fullname: Marchese, V.
  organization: Italy
– sequence: 65
  givenname: E.
  surname: Martínez Robles
  fullname: Martínez Robles, E.
  organization: Spain
– sequence: 66
  givenname: A.
  surname: Maryandyshev
  fullname: Maryandyshev, A.
  organization: Russian Federation
– sequence: 67
  givenname: A.
  surname: Matteelli
  fullname: Matteelli, A.
  organization: Italy
– sequence: 68
  givenname: A.
  surname: Mariani
  fullname: Mariani, A.
  organization: Brazil
– sequence: 69
  givenname: J.
  surname: Mazza-Stalder
  fullname: Mazza-Stalder, J.
  organization: Switzerland
– sequence: 70
  givenname: F.
  surname: Mello
  fullname: Mello, F.
  organization: Brazil
– sequence: 71
  givenname: L.
  surname: Mendoza
  fullname: Mendoza, L.
  organization: Chile
– sequence: 72
  givenname: A.
  surname: Mesi
  fullname: Mesi, A.
  organization: Albania
– sequence: 73
  givenname: S.
  surname: Miliauskas
  fullname: Miliauskas, S.
  organization: Lithuania
– sequence: 74
  givenname: H.
  surname: Mustafa Hamdan
  fullname: Mustafa Hamdan, H.
  organization: Sudan
– sequence: 75
  givenname: N.
  surname: Ndjeka
  fullname: Ndjeka, N.
  organization: South Africa
– sequence: 76
  givenname: M.
  surname: Nieto Marcos
  fullname: Nieto Marcos, M.
  organization: Spain
– sequence: 77
  givenname: T.H.M.
  surname: Ottenhoff
  fullname: Ottenhoff, T.H.M.
  organization: Netherlands
– sequence: 78
  givenname: D.J.
  surname: Palmero
  fullname: Palmero, D.J.
  organization: Argentina
– sequence: 79
  givenname: F.
  surname: Palmieri
  fullname: Palmieri, F.
  organization: Italy
– sequence: 80
  givenname: A.
  surname: Papavasileiou
  fullname: Papavasileiou, A.
  organization: Greece
– sequence: 81
  givenname: M.C.
  surname: Payen
  fullname: Payen, M.C.
  organization: Belgium
– sequence: 82
  givenname: A.
  surname: Pontarelli
  fullname: Pontarelli, A.
  organization: Italy
– sequence: 83
  givenname: M.
  surname: Pretti Dalcolmo
  fullname: Pretti Dalcolmo, M.
  organization: Brazil
– sequence: 84
  givenname: S.
  surname: Quirós Fernandez
  fullname: Quirós Fernandez, S.
  organization: Spain
– sequence: 85
  givenname: R.
  surname: Romero
  fullname: Romero, R.
  organization: South Africa
– sequence: 86
  givenname: D.
  surname: Rossato Silva
  fullname: Rossato Silva, D.
  organization: Brazil
– sequence: 87
  givenname: A.P.
  surname: Santos
  fullname: Santos, A.P.
  organization: Brazil
– sequence: 88
  givenname: B.
  surname: Seaworth
  fullname: Seaworth, B.
  organization: USA
– sequence: 89
  givenname: M.
  surname: Sinitsyn
  fullname: Sinitsyn, M.
  organization: Russian Federation
– sequence: 90
  givenname: A.
  surname: Skrahina
  fullname: Skrahina, A.
  organization: Belarus
– sequence: 91
  givenname: I.
  surname: Solovic
  fullname: Solovic, I.
  organization: Slovakia
– sequence: 92
  givenname: A.
  surname: Spanevello
  fullname: Spanevello, A.
  organization: Italy
– sequence: 93
  givenname: M.
  surname: Tadolini
  fullname: Tadolini, M.
  organization: Italy
– sequence: 94
  givenname: C.
  surname: Torres
  fullname: Torres, C.
  organization: Colombia
– sequence: 95
  givenname: Z.
  surname: Udwadia
  fullname: Udwadia, Z.
  organization: India
– sequence: 96
  givenname: M.
  surname: van den Boom
  fullname: van den Boom, M.
  organization: Denmark
– sequence: 97
  givenname: G.V.
  surname: Volchenkov
  fullname: Volchenkov, G.V.
  organization: Russian Federation
– sequence: 98
  givenname: A.
  surname: Yedilbayev
  fullname: Yedilbayev, A.
  organization: Denmark
– sequence: 99
  givenname: R.
  surname: Zaleskis
  fullname: Zaleskis, R.
  organization: Latvia
– sequence: 100
  givenname: J.P.
  surname: Zellweger
  fullname: Zellweger, J.P.
  organization: Switzerland
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32032752$$D View this record in MEDLINE/PubMed
BookMark eNqFkUtvEzEUhUeoiD7gD7BAXrKZqV_zqthACqVSAakKEjvr2nMndToZp7aHKj-C_4zTNCy6KCvbV-cc2-c7zg5GN2KWvWW0YJRVp8vCLm1XcMppQVlBJX-RHbGmbnJRMnaQ9pyyvK0ZP8yOQ1hSSmVVNa-yQ8Gp4HXJj7I_386vT3-dX-fzT2QFIyxwhWMkridriDZtA4GxI8aNEUwMZ2R2A8OA4wID6cHYcUHiDZIR70mHBjosyDydt28iZrCjNTCQad1BRKI3D9qLwek0nE8avZkGF2wg3zHeO3_7OnvZwxDwzeN6kv388nk--5pf_bi4nH28yk0pZcw5trrvaCmoAdoY3aCRbS2FaaGrS0AhdVvTBpgRsmdai_TrHhvdSqxQQyVOsstdbudgqdbersBvlAOrHgbOLxT4aM2AqtQpwegesKYSGga16Kmue5BCI6ddynq_y1p7dzdhiGplg8FhgBHdFBQXJa-kKAVP0neP0kmvsPt38R5HEjQ7gfEuBI-9MjYmDql9D3ZQjKotebVUW_Jq27KiTCXyycqfWPfpz5o-7EyYyv5t0atgEnSDnfVoYmrDPm8_e2LfI7_Fzf_MfwEaVtq8
CitedBy_id crossref_primary_10_1111_tid_13659
crossref_primary_10_3389_fmed_2025_1596579
crossref_primary_10_1007_s12672_025_02941_1
crossref_primary_10_1055_a_1934_8303
crossref_primary_10_36303_SAGP_1204
crossref_primary_10_1155_2023_6659212
crossref_primary_10_1080_23744235_2020_1806353
crossref_primary_10_7759_cureus_35154
crossref_primary_10_1016_j_bioorg_2020_104054
crossref_primary_10_1007_s00203_025_04415_y
crossref_primary_10_1183_20734735_0149_2021
crossref_primary_10_1128_aac_02192_21
crossref_primary_10_1186_s12879_021_06708_1
crossref_primary_10_1016_j_resinv_2024_01_010
crossref_primary_10_3390_ijerph18126541
crossref_primary_10_1016_j_jgar_2022_09_001
crossref_primary_10_7759_cureus_29389
crossref_primary_10_1007_s12559_024_10259_3
crossref_primary_10_3390_vaccines12060622
crossref_primary_10_1164_rccm_202009_3527OC
crossref_primary_10_1007_s11696_025_04268_1
crossref_primary_10_7759_cureus_38251
crossref_primary_10_1002_slct_202501447
crossref_primary_10_1016_j_jiph_2021_10_016
crossref_primary_10_1016_j_ijtb_2025_08_001
crossref_primary_10_1371_journal_pone_0243610
crossref_primary_10_1186_s12879_024_09106_5
crossref_primary_10_1155_ipid_8811027
crossref_primary_10_1016_j_pulmoe_2020_12_016
crossref_primary_10_1186_s12879_022_07693_9
crossref_primary_10_1159_000537878
crossref_primary_10_3389_fgene_2023_1041892
crossref_primary_10_1080_14656566_2022_2161881
crossref_primary_10_1016_j_jgar_2022_11_012
crossref_primary_10_3389_fmicb_2025_1586476
crossref_primary_10_1016_j_pulmoe_2020_10_005
crossref_primary_10_3389_fmicb_2021_714617
crossref_primary_10_1016_j_drup_2025_101265
crossref_primary_10_1016_j_ejmech_2021_113603
crossref_primary_10_1016_j_ijid_2020_11_007
crossref_primary_10_1111_cbdd_70171
crossref_primary_10_3390_ijms25020983
crossref_primary_10_1016_j_ijid_2020_03_001
crossref_primary_10_1183_23120541_00149_2021
crossref_primary_10_3389_fpubh_2022_1047659
crossref_primary_10_1016_j_ebiom_2022_103993
crossref_primary_10_1016_j_arbres_2022_05_010
crossref_primary_10_1080_07391102_2023_2209648
crossref_primary_10_1080_17460441_2025_2531229
crossref_primary_10_1183_13993003_00493_2022
crossref_primary_10_1186_s12879_022_07598_7
crossref_primary_10_52420_umj_24_3_7
crossref_primary_10_1088_1742_6596_2071_1_012001
crossref_primary_10_4103_ijmy_ijmy_224_23
crossref_primary_10_1007_s11696_025_04102_8
crossref_primary_10_2147_IJGM_S428962
crossref_primary_10_3889_oamjms_2022_8088
crossref_primary_10_1093_cid_ciaa755
crossref_primary_10_1080_07391102_2023_2260483
crossref_primary_10_3390_tropicalmed8020100
crossref_primary_10_1080_24745332_2022_2043055
crossref_primary_10_1080_14787210_2023_2240022
crossref_primary_10_1136_bmjgh_2024_018220
crossref_primary_10_1016_j_molstruc_2023_135325
crossref_primary_10_1146_annurev_pharmtox_052020_094321
crossref_primary_10_1016_j_ijid_2021_02_067
crossref_primary_10_3390_antibiotics10111355
crossref_primary_10_1016_j_jiph_2021_09_030
crossref_primary_10_1080_17512433_2023_2148653
crossref_primary_10_1183_13993003_01727_2020
crossref_primary_10_1016_j_jbc_2021_101287
crossref_primary_10_3389_fmed_2023_1051620
crossref_primary_10_1016_j_micpath_2025_107861
crossref_primary_10_1016_j_ijid_2022_03_026
crossref_primary_10_1016_j_ijid_2023_03_023
crossref_primary_10_3389_fpubh_2024_1431881
crossref_primary_10_3389_fimmu_2022_878471
crossref_primary_10_3390_diagnostics12020438
crossref_primary_10_1016_j_jinf_2021_10_015
crossref_primary_10_1016_j_ijid_2022_08_015
crossref_primary_10_4103_sjcp_sjcp_6_23
crossref_primary_10_1038_s41598_024_73209_x
crossref_primary_10_1039_D2CC02407A
crossref_primary_10_1183_16000617_0205_2023
crossref_primary_10_20473_jkr_v10i1_69932
crossref_primary_10_58838_2075_1230_2025_103_4_24_31
crossref_primary_10_1080_21691401_2025_2531748
crossref_primary_10_47183_mes_2022_013
crossref_primary_10_1080_14656566_2021_1967930
crossref_primary_10_1016_j_bioorg_2022_106250
crossref_primary_10_1080_24745332_2023_2226008
crossref_primary_10_2147_IMCRJ_S300216
crossref_primary_10_1371_journal_pone_0250028
crossref_primary_10_1016_j_ijid_2022_02_043
crossref_primary_10_1177_11786361231152438
crossref_primary_10_2147_IDR_S438184
crossref_primary_10_3390_molecules27030616
crossref_primary_10_1016_j_jiph_2021_10_020
crossref_primary_10_1039_D4SC00721B
crossref_primary_10_3390_jof10080529
crossref_primary_10_3389_fphar_2023_1331371
crossref_primary_10_3390_diagnostics13203246
crossref_primary_10_3390_ijms24065202
crossref_primary_10_1016_j_ijid_2020_02_011
crossref_primary_10_1016_j_pulmoe_2021_02_006
crossref_primary_10_1039_D4MD00221K
crossref_primary_10_4103_ijmy_ijmy_47_21
crossref_primary_10_1136_bmjopen_2022_062857
crossref_primary_10_1371_journal_pone_0279882
crossref_primary_10_1016_j_ijid_2020_10_084
crossref_primary_10_1002_mco2_353
crossref_primary_10_1097_MRM_0000000000000400
Cites_doi 10.1093/cid/cit643
10.1371/journal.pmed.1002591
10.1016/j.ijid.2019.03.036
10.5588/ijtld.13.0834
10.1183/13993003.02184-2018
10.1097/INF.0b013e31829157e9
10.1016/S2213-2600(18)30329-1
10.1016/j.ijid.2017.01.029
10.1164/rccm.201309-1634ST
10.1183/13993003.02292-2017
10.1093/cid/cit655
10.1164/rccm.201909-1874ST
10.1183/13993003.00387-2017
10.1086/655127
10.1038/s41591-018-0224-2
10.1097/MCP.0b013e32835f1bf3
10.1016/S2213-2600(15)00458-0
10.1016/S0041-3879(76)80006-2
10.1093/cid/ciy990
10.5588/ijtld.18.0622
10.1183/09031936.05.00006205
10.1093/cid/ciy787
10.1056/NEJM199404283301718
10.1016/j.rmed.2019.105844
10.1183/09031936.00188313
10.1080/17512433.2018.1421067
10.1183/13993003.00391-2019
10.1111/jpc.14387
10.3201/eid2103.141313
10.1086/647678
10.1183/13993003.00214-2016
10.1183/13993003.01354-2017
10.1590/S1806-37562016000000226
10.5588/ijtld.13.0028
10.1056/NEJMoa1811867
10.1086/513772
10.1097/INF.0000000000000260
10.1016/S1473-3099(19)30307-X
10.1183/13993003.01522-2019
10.1590/1806-3713/e20180324
10.1371/journal.pone.0196003
10.1093/cid/cix208
ContentType Journal Article
Contributor Kuksa, L
Romero, R
Isaakidis, P
García García, J M
Seaworth, B
Blanc, F-X
Martínez Robles, E
Miliauskas, S
Volchenkov, G V
Arkub, T Abu
Mustafa Hamdan, H
Escobar Salinas, N
Formenti, B
Solovic, I
Danila, E
Manika, K
Mendoza, L
Cadiñanos Loidi, J
Mazza-Stalder, J
Palmero, D J
Diktanas, S
Caminero, J A
Magis-Escurra, C
Pretti Dalcolmo, M
Quirós Fernandez, S
Borisov, S
Mello, F
Nieto Marcos, M
Koirala, S
Sinitsyn, M
van den Boom, M
Skrahina, A
Tadolini, M
Cebrian Gallardo, J J
Palmieri, F
Dheda, K
Diel, R
Rossato Silva, D
Kaluzhenina, A
Maryandyshev, A
Papavasileiou, A
Bruchfeld, J
Manga, S
Torres, C
Charalampos
Spanevello, A
Manfrin, V
Santos, A P
Denholm, J
Ottenhoff, T H M
Carvalho, A C
Yedilbayev, A
Davies Forsman, L
Akkerman, O W
Ndjeka, N
Kunst, H
Matteelli, A
Mariani, A
Mesi, A
Aleksa, A
Esposito, S
Gomez Rosso, R
Zellweger, J P
Enwerem, M
Pontarelli, A
Filippov, A
Dobler, C
Goletti, D
Zaleskis, R
Gualano, G
Li, Y
Bernal, E
Belilovski, E
Udwadia, Z
Boeree, M
Marchese, V
Payen, M C
Contributor_xml – sequence: 1
  givenname: T Abu
  surname: Arkub
  fullname: Arkub, T Abu
  organization: Russian Federation
– sequence: 2
  givenname: O W
  surname: Akkerman
  fullname: Akkerman, O W
  organization: Netherlands
– sequence: 3
  givenname: A
  surname: Aleksa
  fullname: Aleksa, A
  organization: Belarus
– sequence: 4
  givenname: E
  surname: Belilovski
  fullname: Belilovski, E
  organization: Russian Federation
– sequence: 5
  givenname: E
  surname: Bernal
  fullname: Bernal, E
  organization: Spain
– sequence: 6
  givenname: F-X
  surname: Blanc
  fullname: Blanc, F-X
  organization: France
– sequence: 7
  givenname: M
  surname: Boeree
  fullname: Boeree, M
  organization: Netherlands
– sequence: 8
  givenname: S
  surname: Borisov
  fullname: Borisov, S
  organization: Russian Federation
– sequence: 9
  givenname: J
  surname: Bruchfeld
  fullname: Bruchfeld, J
  organization: Sweden
– sequence: 10
  givenname: J
  surname: Cadiñanos Loidi
  fullname: Cadiñanos Loidi, J
  organization: Spain
– sequence: 11
  givenname: J A
  surname: Caminero
  fullname: Caminero, J A
  organization: Spain
– sequence: 12
  givenname: A C
  surname: Carvalho
  fullname: Carvalho, A C
  organization: Brazil
– sequence: 13
  givenname: J J
  surname: Cebrian Gallardo
  fullname: Cebrian Gallardo, J J
  organization: Spain
– sequence: 14
  surname: Charalampos
  fullname: Charalampos
  organization: Greece
– sequence: 15
  givenname: E
  surname: Danila
  fullname: Danila, E
  organization: Lithuania
– sequence: 16
  givenname: L
  surname: Davies Forsman
  fullname: Davies Forsman, L
  organization: Sweden
– sequence: 17
  givenname: J
  surname: Denholm
  fullname: Denholm, J
– sequence: 18
  givenname: K
  surname: Dheda
  fullname: Dheda, K
  organization: South Africa
– sequence: 19
  givenname: R
  surname: Diel
  fullname: Diel, R
  organization: Germany
– sequence: 20
  givenname: S
  surname: Diktanas
  fullname: Diktanas, S
  organization: Lithuania
– sequence: 21
  givenname: C
  surname: Dobler
  fullname: Dobler, C
  organization: Australia
– sequence: 22
  givenname: M
  surname: Enwerem
  fullname: Enwerem, M
  organization: South Africa
– sequence: 23
  givenname: S
  surname: Esposito
  fullname: Esposito, S
  organization: Italy
– sequence: 24
  givenname: N
  surname: Escobar Salinas
  fullname: Escobar Salinas, N
  organization: Chile
– sequence: 25
  givenname: A
  surname: Filippov
  fullname: Filippov, A
  organization: Russian Federation
– sequence: 26
  givenname: B
  surname: Formenti
  fullname: Formenti, B
  organization: Italy
– sequence: 27
  givenname: J M
  surname: García García
  fullname: García García, J M
  organization: Spain
– sequence: 28
  givenname: D
  surname: Goletti
  fullname: Goletti, D
  organization: Italy
– sequence: 29
  givenname: R
  surname: Gomez Rosso
  fullname: Gomez Rosso, R
  organization: Paraguay
– sequence: 30
  givenname: G
  surname: Gualano
  fullname: Gualano, G
  organization: Italy
– sequence: 31
  givenname: P
  surname: Isaakidis
  fullname: Isaakidis, P
  organization: South Africa
– sequence: 32
  givenname: A
  surname: Kaluzhenina
  fullname: Kaluzhenina, A
  organization: Russian Federation
– sequence: 33
  givenname: S
  surname: Koirala
  fullname: Koirala, S
  organization: Nepal
– sequence: 34
  givenname: L
  surname: Kuksa
  fullname: Kuksa, L
  organization: Latvia
– sequence: 35
  givenname: H
  surname: Kunst
  fullname: Kunst, H
  organization: UK
– sequence: 36
  givenname: Y
  surname: Li
  fullname: Li, Y
  organization: China
– sequence: 37
  givenname: C
  surname: Magis-Escurra
  fullname: Magis-Escurra, C
  organization: Netherlands
– sequence: 38
  givenname: V
  surname: Manfrin
  fullname: Manfrin, V
  organization: Italy
– sequence: 39
  givenname: S
  surname: Manga
  fullname: Manga, S
  organization: Peru
– sequence: 40
  givenname: K
  surname: Manika
  fullname: Manika, K
  organization: Greece
– sequence: 41
  givenname: V
  surname: Marchese
  fullname: Marchese, V
  organization: Italy
– sequence: 42
  givenname: E
  surname: Martínez Robles
  fullname: Martínez Robles, E
  organization: Spain
– sequence: 43
  givenname: A
  surname: Maryandyshev
  fullname: Maryandyshev, A
  organization: Russian Federation
– sequence: 44
  givenname: A
  surname: Matteelli
  fullname: Matteelli, A
  organization: Italy
– sequence: 45
  givenname: A
  surname: Mariani
  fullname: Mariani, A
  organization: Brazil
– sequence: 46
  givenname: J
  surname: Mazza-Stalder
  fullname: Mazza-Stalder, J
  organization: Switzerland
– sequence: 47
  givenname: F
  surname: Mello
  fullname: Mello, F
  organization: Brazil
– sequence: 48
  givenname: L
  surname: Mendoza
  fullname: Mendoza, L
  organization: Chile
– sequence: 49
  givenname: A
  surname: Mesi
  fullname: Mesi, A
  organization: Albania
– sequence: 50
  givenname: S
  surname: Miliauskas
  fullname: Miliauskas, S
  organization: Lithuania
– sequence: 51
  givenname: H
  surname: Mustafa Hamdan
  fullname: Mustafa Hamdan, H
  organization: Sudan
– sequence: 52
  givenname: N
  surname: Ndjeka
  fullname: Ndjeka, N
  organization: South Africa
– sequence: 53
  givenname: M
  surname: Nieto Marcos
  fullname: Nieto Marcos, M
  organization: Spain
– sequence: 54
  givenname: T H M
  surname: Ottenhoff
  fullname: Ottenhoff, T H M
  organization: Netherlands
– sequence: 55
  givenname: D J
  surname: Palmero
  fullname: Palmero, D J
  organization: Argentina
– sequence: 56
  givenname: F
  surname: Palmieri
  fullname: Palmieri, F
  organization: Italy
– sequence: 57
  givenname: A
  surname: Papavasileiou
  fullname: Papavasileiou, A
  organization: Greece
– sequence: 58
  givenname: M C
  surname: Payen
  fullname: Payen, M C
  organization: Belgium
– sequence: 59
  givenname: A
  surname: Pontarelli
  fullname: Pontarelli, A
  organization: Italy
– sequence: 60
  givenname: M
  surname: Pretti Dalcolmo
  fullname: Pretti Dalcolmo, M
  organization: Brazil
– sequence: 61
  givenname: S
  surname: Quirós Fernandez
  fullname: Quirós Fernandez, S
  organization: Spain
– sequence: 62
  givenname: R
  surname: Romero
  fullname: Romero, R
  organization: South Africa
– sequence: 63
  givenname: D
  surname: Rossato Silva
  fullname: Rossato Silva, D
  organization: Brazil
– sequence: 64
  givenname: A P
  surname: Santos
  fullname: Santos, A P
  organization: Brazil
– sequence: 65
  givenname: B
  surname: Seaworth
  fullname: Seaworth, B
  organization: USA
– sequence: 66
  givenname: M
  surname: Sinitsyn
  fullname: Sinitsyn, M
  organization: Russian Federation
– sequence: 67
  givenname: A
  surname: Skrahina
  fullname: Skrahina, A
  organization: Belarus
– sequence: 68
  givenname: I
  surname: Solovic
  fullname: Solovic, I
  organization: Slovakia
– sequence: 69
  givenname: A
  surname: Spanevello
  fullname: Spanevello, A
  organization: Italy
– sequence: 70
  givenname: M
  surname: Tadolini
  fullname: Tadolini, M
  organization: Italy
– sequence: 71
  givenname: C
  surname: Torres
  fullname: Torres, C
  organization: Colombia
– sequence: 72
  givenname: Z
  surname: Udwadia
  fullname: Udwadia, Z
  organization: India
– sequence: 73
  givenname: M
  surname: van den Boom
  fullname: van den Boom, M
  organization: Denmark
– sequence: 74
  givenname: G V
  surname: Volchenkov
  fullname: Volchenkov, G V
  organization: Russian Federation
– sequence: 75
  givenname: A
  surname: Yedilbayev
  fullname: Yedilbayev, A
  organization: Denmark
– sequence: 76
  givenname: R
  surname: Zaleskis
  fullname: Zaleskis, R
  organization: Latvia
– sequence: 77
  givenname: J P
  surname: Zellweger
  fullname: Zellweger, J P
  organization: Switzerland
Copyright 2020 The Authors
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Copyright_xml – notice: 2020 The Authors
– notice: Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
CorporateAuthor the members of the Global Tuberculosis Network
members of the Global Tuberculosis Network
CorporateAuthor_xml – name: the members of the Global Tuberculosis Network
– name: members of the Global Tuberculosis Network
DBID 6I.
AAFTH
AAYXX
CITATION
NPM
7X8
DOA
DOI 10.1016/j.ijid.2020.01.042
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
PubMed
MEDLINE - Academic
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Public Health
EISSN 1878-3511
EndPage S25
ExternalDocumentID oai_doaj_org_article_5bf1bcbfae704a81a73f0b7fa43be20d
32032752
10_1016_j_ijid_2020_01_042
S120197122030045X
Genre Journal Article
GroupedDBID ---
--K
.1-
.FO
.~1
0R~
1B1
1P~
1~.
1~5
29J
3O-
4.4
457
4G.
53G
5GY
5VS
7-5
71M
7X7
88E
8C1
8FI
8FJ
8FQ
8R4
8R5
AAEDW
AAFWJ
AAIKJ
AALRI
AAQFI
AAQXK
AARKO
AAXUO
AAYWO
ABBQC
ABFRF
ABMAC
ABUWG
ABWVN
ACGFO
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
ADVLN
AEFWE
AEKER
AENEX
AEUPX
AEVXI
AEXQZ
AFJKZ
AFKRA
AFPKN
AFPUW
AFRHN
AFTJW
AGEKW
AGHFR
AGQPQ
AGYEJ
AHMBA
AIGII
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
APXCP
ASPBG
AVWKF
AZFZN
BAWUL
BCNDV
BENPR
BPHCQ
BR6
BVXVI
CCPQU
CS3
DIK
DU5
DWQXO
E3Z
EBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FNPLU
FYUFA
G-Q
GBLVA
GROUPED_DOAJ
GX1
HMCUK
HVGLF
HZ~
IHE
IXB
J1W
KQ8
M1P
M3C
M3G
M41
MO0
N9A
O-L
O9-
OD-
OK1
OO.
OZT
P-8
P-9
P2P
PC.
PHGZM
PHGZT
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
Q2X
Q38
QTD
R2-
ROL
RPZ
RWL
RXW
SDF
SDG
SEL
SES
SEW
SSZ
TAE
UKHRP
UNMZH
Z5R
~HD
0SF
3V.
6I.
AACTN
AAFTH
ABVKL
AFCTW
NCXOZ
RIG
9DU
AAYXX
AFFHD
CITATION
ALIPV
NPM
7X8
ID FETCH-LOGICAL-c544t-2e9bfd0530ca08cb8ec49743c9ad75ae34b9708a1c34f1bb3668fe8b94e6eba63
IEDL.DBID DOA
ISICitedReferencesCount 162
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000521981500003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1201-9712
1878-3511
IngestDate Fri Oct 03 12:39:19 EDT 2025
Sun Sep 28 01:29:02 EDT 2025
Wed Feb 19 02:30:51 EST 2025
Sat Nov 29 06:58:50 EST 2025
Tue Nov 18 21:36:23 EST 2025
Fri Feb 23 02:45:02 EST 2024
Tue Oct 14 19:35:16 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords Prevention
MDR-TB
Treatment
XDR-TB
Diagnosis
Rehabilitation of sequelae
Language English
License This is an open access article under the CC BY-NC-ND license.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c544t-2e9bfd0530ca08cb8ec49743c9ad75ae34b9708a1c34f1bb3668fe8b94e6eba63
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ORCID 0000-0002-8793-9680
0000-0002-2597-574X
0000-0002-5111-5735
0000-0002-1600-4474
0000-0003-2257-3099
0000-0003-3404-2690
0000-0002-2534-2942
0000-0001-6703-0288
0000-0002-3229-2429
OpenAccessLink https://doaj.org/article/5bf1bcbfae704a81a73f0b7fa43be20d
PMID 32032752
PQID 2352643532
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_5bf1bcbfae704a81a73f0b7fa43be20d
proquest_miscellaneous_2352643532
pubmed_primary_32032752
crossref_citationtrail_10_1016_j_ijid_2020_01_042
crossref_primary_10_1016_j_ijid_2020_01_042
elsevier_sciencedirect_doi_10_1016_j_ijid_2020_01_042
elsevier_clinicalkey_doi_10_1016_j_ijid_2020_01_042
PublicationCentury 2000
PublicationDate 2020-03-01
PublicationDateYYYYMMDD 2020-03-01
PublicationDate_xml – month: 03
  year: 2020
  text: 2020-03-01
  day: 01
PublicationDecade 2020
PublicationPlace Canada
PublicationPlace_xml – name: Canada
PublicationTitle International journal of infectious diseases
PublicationTitleAlternate Int J Infect Dis
PublicationYear 2020
Publisher Elsevier Ltd
Elsevier
Publisher_xml – name: Elsevier Ltd
– name: Elsevier
References Akkerman, Aleksa, Alffenaar, Al-Marzouqi, Arias-Guillén, Belilovski (bib0010) 2019; 83
Borisov, Danila, Maryandyshev, Dalcolmo, Miliauskas, Kuksa (bib0040) 2019; 54
Nunn, Phillips, Meredith, Chiang, Conradie, Dalai (bib0155) 2019; 380
Papastavros, Dolovich, Holbrook, Whitehead, Loeb (bib0160) 2002; 167
Petersen, Khamis, Migliori, Bay, Marais, Wejse (bib0165) 2017; 56
Muñoz-Torrico, Rendon, Centis, D’Ambrosio, Fuentes, Torres-Duque (bib0145) 2016; 42
Dharmadhikari, Mphahlele, Venter, Stoltz, Mathebula, Masotla (bib0055) 2014; 18
Kendall, Fofana, Dowdy (bib0090) 2015; 3
Bamrah, Brostrom, Dorina, Setik, Song, Kawamura (bib0030) 2014; 18
Harausz, Garcia-Prats, Law, Schaaf, Kredo, Seddon (bib0065) 2018; 15
Migliori, Nardell, Yedilbayev, D’Ambrosio, Centis, Tadolini (bib0135) 2019; 53
Trieu, Proops, Ahuja (bib0240) 2015; 21
Williams, Ramroop, Shah, Anderson, Das, Riddell (bib0250) 2013; 32
Alffenaar, Heysell, Mpagama (bib0020) 2019; 68
Huynh, Marais (bib0075) 2019; 6
Tiberi, Munoz-Torrico, Rahman, Krutikov, Visca, Silva (bib0235) 2019; 45
Alffenaar, Gumbo, Dooley, Peloquin, McIlleron, Zagorski (bib0015) 2019
Tiberi, Sotgiu, D’Ambrosio, Centis, Abdo Arbex, Alarcon Arrascue (bib0230) 2016; 62
WHO International Clinical Trials Registry Platform. identifier: ISRCTN92634082. Tuberculosis child multidrug-resistant preventive therapy: TB CHAMP trial. Available at
Arbex, Bonini, Kawakame Pirolla, D’Ambrosio, Centis, Migliori (bib0025) 2016
Loveday, Wallengren, Reddy, Besada, Brust, Voce (bib0110) 2018; 13
Migliori, D’Ambrosio, Centis, Van Den Boom, Ehsani, Dara (bib0125) 2018
World Health Organization (bib0295) 2019
Imperial, Nahid, Phillips, Davies, Fielding, Hanna (bib0085) 2018; 24
Menzies (bib0120) 1997; 18
Adler-Shohet, Low, Carson, Girma, Singh (bib0005) 2014; 33
World Health Organization (bib0255) 2015
World Health Organization (bib0280) 2019
World Health Organization (bib0275) 2018
Rouillon, Perdrizet, Parrot (bib0180) 1976; 57
[Last access 9 January 2020].
Cabibbe, Sotgiu, Izco, Migliori (bib0045) 2017; 50
Pontali, Matteelli, Migliori (bib0175) 2013; 19
Marks, Mase, Morris (bib0115) 2017; 64
ClinicalTrials.gov. Identifier: NCT03568383 (bib0050) 2018
Nahid, Mase, Migliori, Sotgiu, Bothamley, Brozek (bib0150) 2019; 200
Spruit, Singh, Garvey, ZuWallack, Nici, Rochester (bib0205) 2013; 188
The Sentinel Project for Pediatric Drug-Resistant Tuberculosis (bib0220) 2018
Borisov, Dheda, Enwerem, Romero Leyet, D’Ambrosio, Centis (bib0035) 2017; 49
Visca, Zampogna, Sotgiu, Centis, Saderi, D’Ambrosio (bib0245) 2019; 53
Schaaf, Garcia-Prats, McKenna, Seddon (bib0185) 2018; 11
Lange, Abubakar, Alffenaar, Bothamley, Caminero, Carvalho (bib0100) 2014; 44
World Health Organization (bib0260) 2015
Miotto, Tessema, Tagliani, Chindelevitch, Starks, Emerson (bib0140) 2017; 50
Zar, Nicol (bib0315) 2019; 144
Migliori, Global Tuberculosis Network (GTN) (bib0130) 2019; 68
Piubello, Souleymane, Hassane-Harouna, Yacouba, Lempens, Assao-Neino (bib0170) 2020; 161
Telzak, Fazal, Pollard, Turett, Justman, Blum (bib0210) 1997; 25
World Health Organization (bib0300) 2019
Seddon, Hesseling, Finlayson, Fielding, Cox, Hughes (bib0190) 2013; 57
Horn, Hewlett, Alfalla, Peterson, Opal (bib0070) 1994; 330
Tiberi, Sotgiu, D’Ambrosio, Centis, Abdo Arbex, Alarcon Arrascue (bib0225) 2016; 47
Knight, McQuaid, Dodd, Houben (bib0095) 2019; 19
Huynh, Vosu, Marais, Britton (bib0080) 2019; 55
World Health Organization (bib0285) 2019
Fitzwater, Caviedes, Gilman, Coronel, LaChira, Salazar (bib0060) 2010; 51
Shah, Yuen, Heo, Tolman, Becerra (bib0200) 2014; 58
World Health Organization (bib0270) 2018
World Health Organization (bib0290) 2019
World Health Organization (bib0265) 2016
Lange, Aarnoutse, Alffenaar, Bothamley, Brinkmann, Costa (bib0105) 2019; 23
The Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad, Ahuja, Akkerman, Alffenaar, Anderson (bib0215) 2018; 392
Seddon, Schaaf, Marais, McKenna, Garcia-Prats, Hesseling (bib0195) 2018; 6
Younossian, Rochat, Ketterer, Wacker, Janssens (bib0310) 2005; 26
Fitzwater (10.1016/j.ijid.2020.01.042_bib0060) 2010; 51
Horn (10.1016/j.ijid.2020.01.042_bib0070) 1994; 330
Zar (10.1016/j.ijid.2020.01.042_bib0315) 2019; 144
ClinicalTrials.gov. Identifier: NCT03568383 (10.1016/j.ijid.2020.01.042_bib0050) 2018
Miotto (10.1016/j.ijid.2020.01.042_bib0140) 2017; 50
Imperial (10.1016/j.ijid.2020.01.042_bib0085) 2018; 24
Seddon (10.1016/j.ijid.2020.01.042_bib0195) 2018; 6
Petersen (10.1016/j.ijid.2020.01.042_bib0165) 2017; 56
Kendall (10.1016/j.ijid.2020.01.042_bib0090) 2015; 3
Borisov (10.1016/j.ijid.2020.01.042_bib0040) 2019; 54
Huynh (10.1016/j.ijid.2020.01.042_bib0080) 2019; 55
Dharmadhikari (10.1016/j.ijid.2020.01.042_bib0055) 2014; 18
Spruit (10.1016/j.ijid.2020.01.042_bib0205) 2013; 188
Trieu (10.1016/j.ijid.2020.01.042_bib0240) 2015; 21
Williams (10.1016/j.ijid.2020.01.042_bib0250) 2013; 32
Tiberi (10.1016/j.ijid.2020.01.042_bib0230) 2016; 62
Cabibbe (10.1016/j.ijid.2020.01.042_bib0045) 2017; 50
Loveday (10.1016/j.ijid.2020.01.042_bib0110) 2018; 13
The Sentinel Project for Pediatric Drug-Resistant Tuberculosis (10.1016/j.ijid.2020.01.042_bib0220) 2018
Menzies (10.1016/j.ijid.2020.01.042_bib0120) 1997; 18
World Health Organization (10.1016/j.ijid.2020.01.042_bib0280) 2019
Nunn (10.1016/j.ijid.2020.01.042_bib0155) 2019; 380
Nahid (10.1016/j.ijid.2020.01.042_bib0150) 2019; 200
World Health Organization (10.1016/j.ijid.2020.01.042_bib0260) 2015
Adler-Shohet (10.1016/j.ijid.2020.01.042_bib0005) 2014; 33
Shah (10.1016/j.ijid.2020.01.042_bib0200) 2014; 58
World Health Organization (10.1016/j.ijid.2020.01.042_bib0255) 2015
Marks (10.1016/j.ijid.2020.01.042_bib0115) 2017; 64
Huynh (10.1016/j.ijid.2020.01.042_bib0075) 2019; 6
Papastavros (10.1016/j.ijid.2020.01.042_bib0160) 2002; 167
World Health Organization (10.1016/j.ijid.2020.01.042_bib0275) 2018
10.1016/j.ijid.2020.01.042_bib0305
World Health Organization (10.1016/j.ijid.2020.01.042_bib0295) 2019
Bamrah (10.1016/j.ijid.2020.01.042_bib0030) 2014; 18
Telzak (10.1016/j.ijid.2020.01.042_bib0210) 1997; 25
Knight (10.1016/j.ijid.2020.01.042_bib0095) 2019; 19
Arbex (10.1016/j.ijid.2020.01.042_bib0025) 2016
Piubello (10.1016/j.ijid.2020.01.042_bib0170) 2020; 161
Borisov (10.1016/j.ijid.2020.01.042_bib0035) 2017; 49
Younossian (10.1016/j.ijid.2020.01.042_bib0310) 2005; 26
Muñoz-Torrico (10.1016/j.ijid.2020.01.042_bib0145) 2016; 42
Tiberi (10.1016/j.ijid.2020.01.042_bib0235) 2019; 45
Tiberi (10.1016/j.ijid.2020.01.042_bib0225) 2016; 47
Lange (10.1016/j.ijid.2020.01.042_bib0100) 2014; 44
Migliori (10.1016/j.ijid.2020.01.042_bib0125) 2018
Harausz (10.1016/j.ijid.2020.01.042_bib0065) 2018; 15
Akkerman (10.1016/j.ijid.2020.01.042_bib0010) 2019; 83
Rouillon (10.1016/j.ijid.2020.01.042_bib0180) 1976; 57
Schaaf (10.1016/j.ijid.2020.01.042_bib0185) 2018; 11
Seddon (10.1016/j.ijid.2020.01.042_bib0190) 2013; 57
Migliori (10.1016/j.ijid.2020.01.042_bib0130) 2019; 68
The Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017 (10.1016/j.ijid.2020.01.042_bib0215) 2018; 392
Alffenaar (10.1016/j.ijid.2020.01.042_bib0015) 2019
Pontali (10.1016/j.ijid.2020.01.042_bib0175) 2013; 19
Visca (10.1016/j.ijid.2020.01.042_bib0245) 2019; 53
World Health Organization (10.1016/j.ijid.2020.01.042_bib0270) 2018
World Health Organization (10.1016/j.ijid.2020.01.042_bib0290) 2019
Lange (10.1016/j.ijid.2020.01.042_bib0105) 2019; 23
Migliori (10.1016/j.ijid.2020.01.042_bib0135) 2019; 53
World Health Organization (10.1016/j.ijid.2020.01.042_bib0265) 2016
Alffenaar (10.1016/j.ijid.2020.01.042_bib0020) 2019; 68
World Health Organization (10.1016/j.ijid.2020.01.042_bib0285) 2019
World Health Organization (10.1016/j.ijid.2020.01.042_bib0300) 2019
References_xml – volume: 3
  start-page: 963
  year: 2015
  end-page: 972
  ident: bib0090
  article-title: Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis
  publication-title: Lancet Respir Med.
– year: 2018
  ident: bib0125
  article-title: Guiding principles to reduce tuberculosis transmission in the WHO European region
– volume: 47
  start-page: 1758
  year: 2016
  end-page: 1766
  ident: bib0225
  article-title: Comparison of effectiveness and safety of imipenem/clavulanate-versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB
  publication-title: Eur Respir J
– volume: 19
  start-page: 903
  year: 2019
  end-page: 912
  ident: bib0095
  article-title: Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling
  publication-title: Lancet Infect Dis
– year: 2018
  ident: bib0050
  article-title: Protecting households on exposure to newly diagnosed index multidrug-resistant tuberculosis patients (PHOENIx MDR-TB)
– volume: 21
  start-page: 500
  year: 2015
  end-page: 503
  ident: bib0240
  article-title: Moxifloxacin prophylaxis against MDR TB, New York, New York, USA
  publication-title: Emerg Infect Dis
– volume: 64
  start-page: 1670
  year: 2017
  end-page: 1677
  ident: bib0115
  article-title: Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrugresistant tuberculosis
  publication-title: Clin Infect Dis
– year: 2015
  ident: bib0260
  article-title: Toolkit to develop a national strategic plan for TB prevention, care and controll: methodology on how to develop a national strategic plan. WHO/HTM/TB/2015.08
– volume: 15
  year: 2018
  ident: bib0065
  article-title: Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis
  publication-title: PLoS Med
– volume: 32
  start-page: 926
  year: 2013
  end-page: 927
  ident: bib0250
  article-title: Management of pediatric contacts of multidrug resistant tuberculosis in the United Kingdom
  publication-title: Pediatr Infect Dis J
– volume: 57
  start-page: 275
  year: 1976
  end-page: 299
  ident: bib0180
  article-title: Transmission of tubercle bacilli: The effects of chemotherapy
  publication-title: Tubercle
– volume: 11
  start-page: 233
  year: 2018
  end-page: 244
  ident: bib0185
  article-title: Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children
  publication-title: Expert Rev Clin Pharmacol
– volume: 24
  start-page: 1708
  year: 2018
  end-page: 1715
  ident: bib0085
  article-title: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis
  publication-title: Nat Med
– year: 2019
  ident: bib0290
  article-title: WHO Meeting Report of a Technical Expert Consultation: accuracy of centralized assays for TB detection and detection of resistance to rifampicin and isoniazid
– volume: 23
  start-page: 645
  year: 2019
  end-page: 662
  ident: bib0105
  article-title: Management of patients with multidrug-resistant tuberculosis
  publication-title: Int J Tuberc Lung Dis
– volume: 18
  start-page: 582
  year: 1997
  end-page: 586
  ident: bib0120
  article-title: Effect of treatment on contagiousness of patients with active pulmonary tuberculosis
  publication-title: Infect Control Hosp Epidemiol
– year: 2018
  ident: bib0275
  article-title: Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis
– volume: 49
  year: 2017
  ident: bib0035
  article-title: Effectiveness and safety of bedaquiline-containing regimens in the treatment of multidrug and extensively drug-resistant tuberculosis: a multicentre study
  publication-title: Eur Respir J
– year: 2018
  ident: bib0220
  article-title: Management of drug-resistant tuberculosis in children: a field guide
– volume: 26
  start-page: 462
  year: 2005
  end-page: 464
  ident: bib0310
  article-title: High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis
  publication-title: Eur Respir J
– volume: 18
  start-page: 912
  year: 2014
  end-page: 918
  ident: bib0030
  article-title: Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012
  publication-title: Int J Tuberc Lung Dis
– volume: 167
  start-page: 131
  year: 2002
  end-page: 136
  ident: bib0160
  article-title: Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis
  publication-title: CMAJ
– year: 2019
  ident: bib0300
  article-title: Rapid communication: key changes to treatment of drug-resistant tuberculosis
– volume: 53
  year: 2019
  ident: bib0245
  article-title: Pulmonary rehabilitation is effective in patients with tuberculosis pulmonary sequelae
  publication-title: Eur Respir J
– volume: 58
  start-page: 381
  year: 2014
  end-page: 391
  ident: bib0200
  article-title: Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis
  publication-title: Clin Infect Dis
– volume: 54
  year: 2019
  ident: bib0040
  article-title: Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report
  publication-title: Eur Respir J
– volume: 19
  start-page: 266
  year: 2013
  end-page: 272
  ident: bib0175
  article-title: Drug-resistant tuberculosis
  publication-title: Curr Opin Pulm Med
– start-page: 337
  year: 2016
  end-page: 341
  ident: bib0025
  article-title: Effectiveness and safety of imipenem/clavulanate and linezolid to treat multidrug and extensively drug-resistant tuberculosis at a referral hospital in Brazil
  publication-title: Rev Port Pneumol
– volume: 50
  year: 2017
  ident: bib0140
  article-title: A standardised method for interpreting the association between mutations and phenotypic drug-resistance in
  publication-title: Eur Respir J
– volume: 330
  start-page: 1241
  year: 1994
  ident: bib0070
  article-title: Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis
  publication-title: N Engl J Med
– volume: 56
  start-page: 34
  year: 2017
  end-page: 38
  ident: bib0165
  article-title: De-isolation of patients with pulmonary tuberculosis after start of treatment-clear, unequivocal guidelines are missing
  publication-title: Int J Infect Dis
– year: 2019
  ident: bib0295
  article-title: Global tuberculosis report 2019
– volume: 33
  start-page: 664
  year: 2014
  end-page: 666
  ident: bib0005
  article-title: Management of latent tuberculosis infection in child contacts of multidrug-resistant tuberculosis
  publication-title: Pediatr Infect Dis J
– volume: 42
  start-page: 374
  year: 2016
  end-page: 385
  ident: bib0145
  article-title: Is there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis?
  publication-title: J Bras Pneumol
– year: 2015
  ident: bib0255
  article-title: The WHO end TB strategy
– volume: 188
  start-page: e13
  year: 2013
  end-page: e64
  ident: bib0205
  article-title: An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation
  publication-title: Am J Respir Crit Care Med
– volume: 161
  start-page: 105844
  year: 2020
  ident: bib0170
  article-title: Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: nationwide programmatic achievements
  publication-title: Respir Med
– volume: 13
  year: 2018
  ident: bib0110
  article-title: MDR-TB patients in KwaZulu-Natal, South Africa: cost-effectiveness of 5 models of care
  publication-title: PLoS One
– volume: 53
  year: 2019
  ident: bib0135
  article-title: Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe
  publication-title: Eur Respir J
– volume: 18
  start-page: 1019
  year: 2014
  end-page: 1025
  ident: bib0055
  article-title: Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis
  publication-title: Int J Tuberc Lung Dis
– volume: 45
  year: 2019
  ident: bib0235
  article-title: Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation
  publication-title: J Bras Pneumol
– volume: 57
  start-page: 1676
  year: 2013
  end-page: 1684
  ident: bib0190
  article-title: Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study
  publication-title: Clin Infect Dis
– volume: 144
  year: 2019
  ident: bib0315
  article-title: Strengthening diagnosis of pulmonary tuberculosis in children: the role of xpert MTB/RIF ultra
  publication-title: Pediatrics
– volume: 50
  year: 2017
  ident: bib0045
  article-title: Genotypic and phenotypic M. tuberculosis resistance: guiding clinicians to prescribe the correct regimens
  publication-title: Eur Respir J
– volume: 44
  start-page: 23
  year: 2014
  end-page: 63
  ident: bib0100
  article-title: Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement
  publication-title: Eur Respir J
– volume: 6
  start-page: 662
  year: 2018
  end-page: 664
  ident: bib0195
  article-title: Time to act on injectable-free regimens for children with multidrug-resistant tuberculosis
  publication-title: Lancet Respir Med
– volume: 62
  start-page: 1188
  year: 2016
  end-page: 1190
  ident: bib0230
  article-title: Effectiveness and safety of imipenem-clavulanate added to an optimized background regimen (OBR) versus OBR control regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis
  publication-title: Clin Infect Dis
– volume: 68
  start-page: 1787
  year: 2019
  end-page: 1789
  ident: bib0130
  article-title: Evolution of programmatic definitions used in tuberculosis prevention and care
  publication-title: Clin Infect Dis
– volume: 6
  year: 2019
  ident: bib0075
  article-title: Multidrug-resistant tuberculosis infection and disease in children: a review of new and repurposed drugs
  publication-title: Ther Adv Infect Dis
– year: 2019
  ident: bib0280
  article-title: WHO guidelines on tuberculosis infection prevention and control, 2019 update
– volume: 200
  start-page: e93
  year: 2019
  end-page: e142
  ident: bib0150
  article-title: Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline
  publication-title: Am J Respir Crit Care Med
– volume: 25
  start-page: 666
  year: 1997
  end-page: 670
  ident: bib0210
  article-title: Factors influencing time to sputum conversion among patients with smear-positive pulmonary tuberculosis
  publication-title: Clin Infect Dis
– year: 2016
  ident: bib0265
  article-title: The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents: interim policy guidance. WHO/HTM/TB/2016.14
– year: 2019
  ident: bib0285
  article-title: WHO consolidated guidelines on drug-resistant tuberculosis treatment
– volume: 392
  start-page: 821
  year: 2018
  end-page: 834
  ident: bib0215
  article-title: Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis
  publication-title: Lancet
– reference: . [Last access 9 January 2020].
– year: 2018
  ident: bib0270
  article-title: The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide
– volume: 83
  start-page: 72
  year: 2019
  end-page: 76
  ident: bib0010
  article-title: Surveillance of adverse events in the treatment of drug-resistant tuberculosis: a global feasibility study
  publication-title: Int J Infect Dis
– volume: 68
  start-page: 1065
  year: 2019
  end-page: 1066
  ident: bib0020
  article-title: Therapeutic drug monitoring: the need for practical guidance
  publication-title: Clin Infect Dis
– volume: 51
  start-page: 371
  year: 2010
  end-page: 378
  ident: bib0060
  article-title: Prolonged infectiousness of tuberculosis patients in a directly observed therapy short-course program with standardized therapy
  publication-title: Clin Infect Dis
– reference: WHO International Clinical Trials Registry Platform. identifier: ISRCTN92634082. Tuberculosis child multidrug-resistant preventive therapy: TB CHAMP trial. Available at
– year: 2019
  ident: bib0015
  article-title: Integrating pharmacokinetics and pharmacodynamics in operational research to End TB
  publication-title: Clin Infect Dis
– volume: 55
  start-page: 981
  year: 2019
  end-page: 984
  ident: bib0080
  article-title: Multidrug-resistant tuberculous meningitis in a returned traveller
  publication-title: J Paediatr Child Health
– volume: 380
  start-page: 1201
  year: 2019
  end-page: 1213
  ident: bib0155
  article-title: A trial of a shorter regimen for rifampin-resistant tuberculosis
  publication-title: N Engl J Med
– volume: 58
  start-page: 381
  issue: February (3)
  year: 2014
  ident: 10.1016/j.ijid.2020.01.042_bib0200
  article-title: Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/cit643
– volume: 15
  year: 2018
  ident: 10.1016/j.ijid.2020.01.042_bib0065
  article-title: Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.1002591
– volume: 83
  start-page: 72
  issue: June
  year: 2019
  ident: 10.1016/j.ijid.2020.01.042_bib0010
  article-title: Surveillance of adverse events in the treatment of drug-resistant tuberculosis: a global feasibility study
  publication-title: Int J Infect Dis
  doi: 10.1016/j.ijid.2019.03.036
– year: 2018
  ident: 10.1016/j.ijid.2020.01.042_bib0270
– year: 2018
  ident: 10.1016/j.ijid.2020.01.042_bib0125
– volume: 18
  start-page: 1019
  year: 2014
  ident: 10.1016/j.ijid.2020.01.042_bib0055
  article-title: Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis
  publication-title: Int J Tuberc Lung Dis
  doi: 10.5588/ijtld.13.0834
– volume: 53
  issue: 3
  year: 2019
  ident: 10.1016/j.ijid.2020.01.042_bib0245
  article-title: Pulmonary rehabilitation is effective in patients with tuberculosis pulmonary sequelae
  publication-title: Eur Respir J
  doi: 10.1183/13993003.02184-2018
– volume: 32
  start-page: 926
  year: 2013
  ident: 10.1016/j.ijid.2020.01.042_bib0250
  article-title: Management of pediatric contacts of multidrug resistant tuberculosis in the United Kingdom
  publication-title: Pediatr Infect Dis J
  doi: 10.1097/INF.0b013e31829157e9
– volume: 6
  start-page: 662
  issue: September (9)
  year: 2018
  ident: 10.1016/j.ijid.2020.01.042_bib0195
  article-title: Time to act on injectable-free regimens for children with multidrug-resistant tuberculosis
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(18)30329-1
– volume: 56
  start-page: 34
  issue: March
  year: 2017
  ident: 10.1016/j.ijid.2020.01.042_bib0165
  article-title: De-isolation of patients with pulmonary tuberculosis after start of treatment-clear, unequivocal guidelines are missing
  publication-title: Int J Infect Dis
  doi: 10.1016/j.ijid.2017.01.029
– volume: 188
  start-page: e13
  issue: 8
  year: 2013
  ident: 10.1016/j.ijid.2020.01.042_bib0205
  article-title: An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201309-1634ST
– volume: 50
  year: 2017
  ident: 10.1016/j.ijid.2020.01.042_bib0045
  article-title: Genotypic and phenotypic M. tuberculosis resistance: guiding clinicians to prescribe the correct regimens
  publication-title: Eur Respir J
  doi: 10.1183/13993003.02292-2017
– volume: 57
  start-page: 1676
  year: 2013
  ident: 10.1016/j.ijid.2020.01.042_bib0190
  article-title: Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/cit655
– volume: 200
  start-page: e93
  issue: November (10)
  year: 2019
  ident: 10.1016/j.ijid.2020.01.042_bib0150
  article-title: Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201909-1874ST
– volume: 49
  issue: 5
  year: 2017
  ident: 10.1016/j.ijid.2020.01.042_bib0035
  article-title: Effectiveness and safety of bedaquiline-containing regimens in the treatment of multidrug and extensively drug-resistant tuberculosis: a multicentre study
  publication-title: Eur Respir J
  doi: 10.1183/13993003.00387-2017
– volume: 51
  start-page: 371
  issue: 4
  year: 2010
  ident: 10.1016/j.ijid.2020.01.042_bib0060
  article-title: Prolonged infectiousness of tuberculosis patients in a directly observed therapy short-course program with standardized therapy
  publication-title: Clin Infect Dis
  doi: 10.1086/655127
– ident: 10.1016/j.ijid.2020.01.042_bib0305
– volume: 24
  start-page: 1708
  issue: November (11)
  year: 2018
  ident: 10.1016/j.ijid.2020.01.042_bib0085
  article-title: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis
  publication-title: Nat Med
  doi: 10.1038/s41591-018-0224-2
– volume: 19
  start-page: 266
  issue: May (3)
  year: 2013
  ident: 10.1016/j.ijid.2020.01.042_bib0175
  article-title: Drug-resistant tuberculosis
  publication-title: Curr Opin Pulm Med
  doi: 10.1097/MCP.0b013e32835f1bf3
– volume: 3
  start-page: 963
  issue: December (12)
  year: 2015
  ident: 10.1016/j.ijid.2020.01.042_bib0090
  article-title: Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis
  publication-title: Lancet Respir Med.
  doi: 10.1016/S2213-2600(15)00458-0
– year: 2019
  ident: 10.1016/j.ijid.2020.01.042_bib0285
– volume: 57
  start-page: 275
  year: 1976
  ident: 10.1016/j.ijid.2020.01.042_bib0180
  article-title: Transmission of tubercle bacilli: The effects of chemotherapy
  publication-title: Tubercle
  doi: 10.1016/S0041-3879(76)80006-2
– start-page: 337
  issue: 6
  year: 2016
  ident: 10.1016/j.ijid.2020.01.042_bib0025
  article-title: Effectiveness and safety of imipenem/clavulanate and linezolid to treat multidrug and extensively drug-resistant tuberculosis at a referral hospital in Brazil
  publication-title: Rev Port Pneumol
– volume: 62
  start-page: 1188
  issue: May (9)
  year: 2016
  ident: 10.1016/j.ijid.2020.01.042_bib0230
  article-title: Effectiveness and safety of imipenem-clavulanate added to an optimized background regimen (OBR) versus OBR control regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis
  publication-title: Clin Infect Dis
– volume: 68
  start-page: 1787
  issue: May (10)
  year: 2019
  ident: 10.1016/j.ijid.2020.01.042_bib0130
  article-title: Evolution of programmatic definitions used in tuberculosis prevention and care
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciy990
– issue: September
  year: 2019
  ident: 10.1016/j.ijid.2020.01.042_bib0015
  article-title: Integrating pharmacokinetics and pharmacodynamics in operational research to End TB
  publication-title: Clin Infect Dis
– year: 2018
  ident: 10.1016/j.ijid.2020.01.042_bib0220
– volume: 23
  start-page: 645
  issue: 6
  year: 2019
  ident: 10.1016/j.ijid.2020.01.042_bib0105
  article-title: Management of patients with multidrug-resistant tuberculosis
  publication-title: Int J Tuberc Lung Dis
  doi: 10.5588/ijtld.18.0622
– volume: 26
  start-page: 462
  year: 2005
  ident: 10.1016/j.ijid.2020.01.042_bib0310
  article-title: High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis
  publication-title: Eur Respir J
  doi: 10.1183/09031936.05.00006205
– volume: 68
  start-page: 1065
  issue: March (6)
  year: 2019
  ident: 10.1016/j.ijid.2020.01.042_bib0020
  article-title: Therapeutic drug monitoring: the need for practical guidance
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciy787
– volume: 330
  start-page: 1241
  issue: April (17)
  year: 1994
  ident: 10.1016/j.ijid.2020.01.042_bib0070
  article-title: Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199404283301718
– volume: 161
  start-page: 105844
  year: 2020
  ident: 10.1016/j.ijid.2020.01.042_bib0170
  article-title: Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: nationwide programmatic achievements
  publication-title: Respir Med
  doi: 10.1016/j.rmed.2019.105844
– volume: 44
  start-page: 23
  issue: 1
  year: 2014
  ident: 10.1016/j.ijid.2020.01.042_bib0100
  article-title: Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement
  publication-title: Eur Respir J
  doi: 10.1183/09031936.00188313
– volume: 11
  start-page: 233
  year: 2018
  ident: 10.1016/j.ijid.2020.01.042_bib0185
  article-title: Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children
  publication-title: Expert Rev Clin Pharmacol
  doi: 10.1080/17512433.2018.1421067
– volume: 53
  year: 2019
  ident: 10.1016/j.ijid.2020.01.042_bib0135
  article-title: Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe
  publication-title: Eur Respir J
  doi: 10.1183/13993003.00391-2019
– volume: 55
  start-page: 981
  issue: August (8)
  year: 2019
  ident: 10.1016/j.ijid.2020.01.042_bib0080
  article-title: Multidrug-resistant tuberculous meningitis in a returned traveller
  publication-title: J Paediatr Child Health
  doi: 10.1111/jpc.14387
– year: 2016
  ident: 10.1016/j.ijid.2020.01.042_bib0265
– volume: 21
  start-page: 500
  issue: March (3)
  year: 2015
  ident: 10.1016/j.ijid.2020.01.042_bib0240
  article-title: Moxifloxacin prophylaxis against MDR TB, New York, New York, USA
  publication-title: Emerg Infect Dis
  doi: 10.3201/eid2103.141313
– volume: 18
  start-page: 582
  year: 1997
  ident: 10.1016/j.ijid.2020.01.042_bib0120
  article-title: Effect of treatment on contagiousness of patients with active pulmonary tuberculosis
  publication-title: Infect Control Hosp Epidemiol
  doi: 10.1086/647678
– volume: 47
  start-page: 1758
  issue: June (6)
  year: 2016
  ident: 10.1016/j.ijid.2020.01.042_bib0225
  article-title: Comparison of effectiveness and safety of imipenem/clavulanate-versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB
  publication-title: Eur Respir J
  doi: 10.1183/13993003.00214-2016
– year: 2015
  ident: 10.1016/j.ijid.2020.01.042_bib0255
– volume: 50
  year: 2017
  ident: 10.1016/j.ijid.2020.01.042_bib0140
  article-title: A standardised method for interpreting the association between mutations and phenotypic drug-resistance in Mycobacterium tuberculosis
  publication-title: Eur Respir J
  doi: 10.1183/13993003.01354-2017
– year: 2019
  ident: 10.1016/j.ijid.2020.01.042_bib0290
– volume: 42
  start-page: 374
  issue: 5
  year: 2016
  ident: 10.1016/j.ijid.2020.01.042_bib0145
  article-title: Is there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis?
  publication-title: J Bras Pneumol
  doi: 10.1590/S1806-37562016000000226
– volume: 18
  start-page: 912
  issue: 8
  year: 2014
  ident: 10.1016/j.ijid.2020.01.042_bib0030
  article-title: Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012
  publication-title: Int J Tuberc Lung Dis
  doi: 10.5588/ijtld.13.0028
– volume: 380
  start-page: 1201
  year: 2019
  ident: 10.1016/j.ijid.2020.01.042_bib0155
  article-title: A trial of a shorter regimen for rifampin-resistant tuberculosis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1811867
– year: 2015
  ident: 10.1016/j.ijid.2020.01.042_bib0260
– volume: 25
  start-page: 666
  year: 1997
  ident: 10.1016/j.ijid.2020.01.042_bib0210
  article-title: Factors influencing time to sputum conversion among patients with smear-positive pulmonary tuberculosis
  publication-title: Clin Infect Dis
  doi: 10.1086/513772
– volume: 33
  start-page: 664
  year: 2014
  ident: 10.1016/j.ijid.2020.01.042_bib0005
  article-title: Management of latent tuberculosis infection in child contacts of multidrug-resistant tuberculosis
  publication-title: Pediatr Infect Dis J
  doi: 10.1097/INF.0000000000000260
– volume: 19
  start-page: 903
  issue: 8
  year: 2019
  ident: 10.1016/j.ijid.2020.01.042_bib0095
  article-title: Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(19)30307-X
– year: 2018
  ident: 10.1016/j.ijid.2020.01.042_bib0275
– year: 2019
  ident: 10.1016/j.ijid.2020.01.042_bib0295
– volume: 54
  issue: 6
  year: 2019
  ident: 10.1016/j.ijid.2020.01.042_bib0040
  article-title: Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report
  publication-title: Eur Respir J
  doi: 10.1183/13993003.01522-2019
– volume: 45
  issue: 2
  year: 2019
  ident: 10.1016/j.ijid.2020.01.042_bib0235
  article-title: Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation
  publication-title: J Bras Pneumol
  doi: 10.1590/1806-3713/e20180324
– volume: 392
  start-page: 821
  issue: September (10150)
  year: 2018
  ident: 10.1016/j.ijid.2020.01.042_bib0215
  article-title: Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis
  publication-title: Lancet
– year: 2019
  ident: 10.1016/j.ijid.2020.01.042_bib0280
– volume: 13
  issue: 4
  year: 2018
  ident: 10.1016/j.ijid.2020.01.042_bib0110
  article-title: MDR-TB patients in KwaZulu-Natal, South Africa: cost-effectiveness of 5 models of care
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0196003
– volume: 167
  start-page: 131
  year: 2002
  ident: 10.1016/j.ijid.2020.01.042_bib0160
  article-title: Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis
  publication-title: CMAJ
– volume: 6
  issue: July
  year: 2019
  ident: 10.1016/j.ijid.2020.01.042_bib0075
  article-title: Multidrug-resistant tuberculosis infection and disease in children: a review of new and repurposed drugs
  publication-title: Ther Adv Infect Dis
– year: 2018
  ident: 10.1016/j.ijid.2020.01.042_bib0050
– volume: 144
  issue: November (5)
  year: 2019
  ident: 10.1016/j.ijid.2020.01.042_bib0315
  article-title: Strengthening diagnosis of pulmonary tuberculosis in children: the role of xpert MTB/RIF ultra
  publication-title: Pediatrics
– volume: 64
  start-page: 1670
  year: 2017
  ident: 10.1016/j.ijid.2020.01.042_bib0115
  article-title: Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrugresistant tuberculosis
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/cix208
– year: 2019
  ident: 10.1016/j.ijid.2020.01.042_bib0300
SSID ssj0004668
Score 2.6178098
SecondaryResourceType review_article
Snippet •Updated clinical guidance on MDR-TB is needed.•Several new MDR-TB diagnostics have been recently approved by WHO to complement existing tools.•To design a...
The continuous flow of new research articles on MDR-TB diagnosis, treatment, prevention and rehabilitation requires frequent update of existing guidelines....
SourceID doaj
proquest
pubmed
crossref
elsevier
SourceType Open Website
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage S15
SubjectTerms Diagnosis
MDR-TB
Prevention
Rehabilitation of sequelae
Treatment
XDR-TB
Title MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network
URI https://www.clinicalkey.com/#!/content/1-s2.0-S120197122030045X
https://dx.doi.org/10.1016/j.ijid.2020.01.042
https://www.ncbi.nlm.nih.gov/pubmed/32032752
https://www.proquest.com/docview/2352643532
https://doaj.org/article/5bf1bcbfae704a81a73f0b7fa43be20d
Volume 92
WOSCitedRecordID wos000521981500003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1878-3511
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0004668
  issn: 1201-9712
  databaseCode: DOA
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagQggJISiv5VENEjcU6thJnHCjLRWXrlC1SHuzxo6Ntmqz1WaD1B_R_8w4TiJ6oL1wjWzH9ow9n-2Zbxj7mJrSkyHwiUJnErIQJkGC-gm3XhZKIlmYsk82oebzcrmsfvyV6iv4hEV64Dhx-7nxqbHGo1M8wzJFJT03ymMmjRO8DrsvoZ7xMDVFRMYgODJvSaVSMYTLRM-u1dkqcIQK3hN2ZuKGSeqZ-29Ypn8hz94CHT9lTwboCF9jl5-xe67ZZQ9PhsfxXfY4XsFBjCx6zq5Pjk73l0enyeIALiYvF1h7GMhUW8CmhuCsjnbbfoHDMbFKCx6pzV9A6BAId0Ptghv9ZyClgjAkGAMqobsMVwZgrvqyMYMALDrjNrY7X7erFubR0fwF-3n8bXH4PRmyLyQ2z7JtIlxlfE1rlFvkpTWlsxkdPqStsFY5OpmZSvESUyszEpGRNOXelabKXOEMFvIl22nWjXvNwAs0yhDyFDzwCyKpR13UeVEZ5FgoO2PpKABtB2rykCHjXI8-aGc6CE2HEWqeahLajH2a6lxGYo5bSx8EuU4lA6l2_4FUTQ-qpu9StRmTo1bocZppp6WGVrf-Op9qDagmopU7630YFU_Tkg_vONi4dddqEXIaEMyVVOZV1MhpYFJwKVQu3vyPAb9lj0KHosvdO7az3XTuPXtgf29X7WaP3VfLcq9fd38AVzQvrA
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MDR%2FXDR-TB+management+of+patients+and+contacts%3A+Challenges+facing+the+new+decade.+The+2020+clinical+update+by+the+Global+Tuberculosis+Network&rft.jtitle=International+journal+of+infectious+diseases&rft.au=Migliori%2C+Giovanni+Battista&rft.au=Tiberi%2C+Simon&rft.au=Zumla%2C+Alimuddin&rft.au=Petersen%2C+Eskild&rft.date=2020-03-01&rft.pub=Elsevier+Ltd&rft.issn=1201-9712&rft.volume=92&rft.spage=S15&rft.epage=S25&rft_id=info:doi/10.1016%2Fj.ijid.2020.01.042&rft.externalDocID=S120197122030045X
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1201-9712&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1201-9712&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1201-9712&client=summon